Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Cyclerion Therapeutics (CYCN) Leases (2019 - 2023)

Cyclerion Therapeutics has reported Leases over the past 5 years, most recently at $1.1 million for Q2 2023.

  • Quarterly results put Leases at $1.1 million for Q2 2023, down 14.12% from a year ago — trailing twelve months through Jun 2023 was $1.1 million (down 14.12% YoY), and the annual figure for FY2022 was $1.2 million, down 13.12%.
  • Leases for Q2 2023 was $1.1 million at Cyclerion Therapeutics, down from $1.2 million in the prior quarter.
  • Over the last five years, Leases for CYCN hit a ceiling of $70.3 million in Q2 2019 and a floor of $1.1 million in Q2 2023.
  • Median Leases over the past 5 years was $6.3 million (2021), compared with a mean of $26.9 million.
  • Peak annual rise in Leases hit 12.77% in 2022, while the deepest fall reached 96.8% in 2022.
  • Cyclerion Therapeutics' Leases stood at $68.1 million in 2019, then tumbled by 36.3% to $43.4 million in 2020, then crashed by 96.77% to $1.4 million in 2021, then fell by 13.12% to $1.2 million in 2022, then dropped by 7.64% to $1.1 million in 2023.
  • The last three reported values for Leases were $1.1 million (Q2 2023), $1.2 million (Q1 2023), and $1.2 million (Q4 2022) per Business Quant data.